Sutro Biopharma (STRO) Net Cash Flow (2017 - 2025)

Sutro Biopharma has disclosed Net Cash Flow across 9 years of filings, most recently posting -$7.8 million for Q4 2025.

• Net Cash Flow for Q4 2025 came in at -$7.8 million, down 149.58% year-over-year; the trailing twelve-month figure through Dec 2025 was -$132.2 million (down 209.21% YoY), and the FY2025 annual result was -$132.2 million, down 209.21% from the prior year.
• Net Cash Flow came in at -$7.8 million for Q4 2025 at Sutro Biopharma, down from $1.9 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $172.6 million in Q2 2023 to a low of -$153.3 million in Q3 2023.
• The 5-year median for Net Cash Flow is -$903000.0 (2021), against an average of -$7.4 million.
• Across the five-year window, Net Cash Flow sank 21127.27% in 2021 and soared 8648.08% in 2022, its largest moves.
• Sutro Biopharma's Net Cash Flow stood at -$293000.0 in 2021, then slumped by 16802.73% to -$49.5 million in 2022, then jumped by 74.63% to -$12.6 million in 2023, then soared by 225.15% to $15.7 million in 2024, then slumped by 149.58% to -$7.8 million in 2025.
• The last three Net Cash Flow figures came in at -$7.8 million (Q4 2025), $1.9 million (Q3 2025), and -$42.2 million (Q2 2025), per Business Quant data.